Mary Ann Liebert: Gene Therapy Prevents Chronic Disorders Associated With Alcohol Exposure in ALDH2 Deficiency
February 13, 2020
February 13, 2020
NEW ROCHELLE, New York, Feb. 13 -- Mary Ann Liebert Inc. issued the following news release:
A new study has shown that gene therapy to treat one of the most common hereditary disorders, aldehyde dehydrogenase type 2 (ALDH2) deficiency, may prevent increased risk for esophageal cancer and osteoporosis associated with chronic alcohol exposure. The study, performed in a mouse model of ALDH2, is published in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publis . . .
A new study has shown that gene therapy to treat one of the most common hereditary disorders, aldehyde dehydrogenase type 2 (ALDH2) deficiency, may prevent increased risk for esophageal cancer and osteoporosis associated with chronic alcohol exposure. The study, performed in a mouse model of ALDH2, is published in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publis . . .